Metabolic/Obesity Approved Deal Benchmarks — Ex-US

Understanding Metabolic/Obesity Deal Benchmarks at Approved

Approved Metabolic/Obesity licensing deals in Ex-US territory command a median upfront payment of $1.6B, with values ranging from $1.2B at the low end to $2.0B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $3.4B to $4.6B, with a median of $4.0B. Royalty rates for metabolic/obesity assets at this stage typically fall between 18.2% and 29.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.